Explaination of New Guideline for Post-approval Changes to Chemical Drug in Combination with the Post-approval Change Managements in China, the United States and Europe

ZHANG Baomei, LU Xiaojun

PDF(1848 KB)
主办：上海医药工业研究院
　　　中国药学会
　　　中国化学制药工业协会
ISSN 1001-8255   CN 31-1243/R   ZYGZEA
Chinese Journal of Pharmaceuticals
PDF(1848 KB)
Chinese Journal of Pharmaceuticals ›› 2022, Vol. 53 ›› Issue (07) : 1056-1061. DOI: 10.16522/j.cnki.cjph.2022.07.020
Pharmaceutical Management & Information

Explaination of New Guideline for Post-approval Changes to Chemical Drug in Combination with the Post-approval Change Managements in China, the United States and Europe

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 53(07): 1056-1061 https://doi.org/10.16522/j.cnki.cjph.2022.07.020

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1848 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉